Journey Medical Corp
DERM
|
$3.59
1.41%
1.39%
75K
|
(0.0% 1d) (21.2% 1m) (112.0% 1y) (0.0% 2d) (0.0% 3d) (1.7% 7d) (100.7% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 50,016,993
https://journeymedicalcorp.com
Sec Filling | Patents | 2021 employees
Journey is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The Journey team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey was formed in 2014 and is a subsidiary of Fortress Biotech, Inc. Journey’s core purpose is to positively impact people’s lives and well-being by providing effective solutions for treating skin conditions, healing wounds and supporting healthy skin.
brands skin
add to watch list Paper trade email alert is off
Press-releases
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
| Email alert
Add to watchlist
CKPT | $1.43 -1.38% -1.4% 350K
|
Health Technology
| Email alert
Add to watchlist
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
| Email alert
Add to watchlist
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
| Email alert
Add to watchlist
DERM | $3.59 1.41% 1.39% 75K
|
| Email alert
Add to watchlist
biotech financial results
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Published: 2024-03-21 (Crawled : 20:00) - globenewswire.com
DERM | $3.59 1.41% 1.39% 75K
|
|
| O: -8.38%
H: 1.8%
C: -5.71%
SWKH | $17.205 -0.26% -0.26% 7.1K
|
Miscellaneous
|
| O: -1.23%
H: 4.63%
C: -0.68%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -1.02%
H: 3.08%
C: -0.77%
corporation medical financial results
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Published: 2024-03-18 (Crawled : 12:30) - globenewswire.com
DERM | $3.59 1.41% 1.39% 75K
|
|
| O: 2.94%
H: 14.57%
C: 6.86%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 3.36%
H: 0.5%
C: -4.0%
dfd-29 fda drug corporation treatment medical application
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Published: 2024-03-15 (Crawled : 12:30) - globenewswire.com
DERM | $3.59 1.41% 1.39% 75K
|
|
| O: -5.19%
H: 10.03%
C: 3.34%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 2.98%
H: 15.03%
C: 11.85%
year corporation medical financial results
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
Published: 2024-03-13 (Crawled : 12:30) - globenewswire.com
DERM | $3.59 1.41% 1.39% 75K
|
|
| O: 0.0%
H: 6.9%
C: -2.01%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -0.78%
H: 1.57%
C: -4.71%
conference corporation medical
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Published: 2024-03-11 (Crawled : 12:30) - globenewswire.com
DERM | $3.59 1.41% 1.39% 75K
|
|
| O: -1.45%
H: 0.88%
C: -0.88%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -0.48%
H: 2.87%
C: -4.31%
dfd-29 presentation corporation meeting impact medical trial
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
DERM | $3.59 1.41% 1.39% 75K
|
|
| O: 0.0%
H: 3.78%
C: -0.89%
OCUP | News | $1.53 1.33% 1.31% 140K
|
Health Technology
|
| O: 0.0%
H: 2.14%
C: 1.17%
pharma key
Lyme Disease Treatment Market is Expected to Showcase Significant Growth by 2032, Assesses DelveInsight | Key Companies - Pfizer, ModernaTX, Tarsus Pharmaceuticals, Valneva, Cortene
Published: 2024-01-15 (Crawled : 22:00) - prnewswire.com
DERM | $3.59 1.41% 1.39% 75K
|
|
| O: 1.45%
H: 8.38%
C: 6.95%
VYNE | $2.345 -0.21% -0.21% 30K
|
Health Technology
|
| O: 0.0%
H: 2.08%
C: -1.46%
TARS | $33.73 4.46% 4.27% 220K
|
Health Technology
|
| O: 0.14%
H: 2.58%
C: 2.17%
disease companies expected treatment key growth market
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Published: 2024-01-05 (Crawled : 13:30) - globenewswire.com
DERM | $3.59 1.41% 1.39% 75K
|
|
| O: 2.82%
H: 4.7%
C: -1.17%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: -0.8%
H: 4.03%
C: -2.42%
dfd-29 fda drug corporation treat medical application
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
Published: 2024-01-02 (Crawled : 21:00) - globenewswire.com
DERM | $3.59 1.41% 1.39% 75K
|
|
| O: -3.87%
H: 3.51%
C: -4.6%
SWKH | $17.205 -0.26% -0.26% 7.1K
|
Miscellaneous
|
| O: 0.39%
H: 0.0%
C: -4.16%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 1.12%
H: 5.51%
C: -8.82%
million corporation medical
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Last 48 Hours Insiders Buying
MEGI | $11.975 1.87% 0.04% 140K
|
|
00:30
CTRN P 29000 | $22.25 0.14% 0.13% 100K
|
Retail Trade
|
22:00
CONN | $3.71 1.37% 1.35% 72K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.6897 39.71% 2.3K
|
Utilities
|
18:30
CMTV P 700 | $15.74 17.43% 12K
|
Finance and Insurance
|
18:30
FNB | $13.63 2.17% 0.0% 2.5M
|
Finance
|
17:30
RMCF | $3.57 0.28% 2.8K
|
Consumer Non-Durables
|
20:10